ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiotherapy helps people with esophageal cancer live longer and delay recurrence. About 700 participants who cannot have surgery will receive either pembrolizumab or a placeb…

This phase 3 trial tested whether adding the immunotherapy drug tislelizumab to standard chemoradiotherapy helps people with localized esophageal squamous cell carcinoma. 370 participants received either tislelizumab or a placebo alongside chemotherapy and radiation. The study me…

This study tested several combinations of the immunotherapy drug pembrolizumab (Keytruda) with other drugs in 90 people with advanced esophageal cancer that had already progressed after one prior treatment. The goal was to see if these combinations are safe and can shrink tumors …

This study looked at 200 people with advanced esophageal cancer to compare two treatments before surgery: immunotherapy combined with chemotherapy, versus chemotherapy plus radiation. Both treatments led to similar long-term survival rates. The immunotherapy combo may offer extra…

This study looks back at medical records of people with esophageal squamous cell carcinoma who had immunotherapy and chemotherapy before surgery, followed by complete tumor removal. The goal is to see if adding radiotherapy after surgery, and how many lymph nodes were removed, af…